Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 18/20 | 0.65 |
| ▸ | KIF23 | Q02241 | 1/20 | 0.61 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | PDE6D | O43924 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5113656 | 0.93 | KIF11 (0.56) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL5113750 | 0.89 | KIF11 (0.62) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL5058375 | 0.86 | KIF11 (0.65) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL5062151 | 0.86 | KIF11 (0.65) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL5062445 | 0.86 | KIF11 (0.65) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL5058368 | 0.86 | KIF11 (0.61) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL5058399 | 0.86 | KIF11 (0.65) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL5062153 | 0.86 | KIF11 (0.65) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL5065921 | 0.86 | KIF11 (0.61) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL5062764 | 0.86 | KIF11 (0.65) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378411-B2 | Substituted thienopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2008-05-27 | — | — | US | claimed |
| EP-1463733-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2007-09-05 | — | — | EP | claimed |
| EP-1463733-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-01-11 | — | — | EP | claimed |
| US-20050228003-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-10-13 | — | — | US | claimed |
| EP-1463733-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2004-10-06 | — | — | EP | claimed |
| WO-2003050064-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-06-19 | — | — | WO | claimed |
| US-7378411-B2 | Substituted thienopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378411-B2 | Substituted thienopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378411-B2 | Substituted thienopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2008-05-27 | — | — | US | disclosed |
| EP-1463733-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1463733-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1463733-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050228003-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-10-13 | — | — | US | disclosed |
| EP-1463733-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003050064-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228003-A1 | Mitotic kinesin inhibitors | KIF5B, KIF18B, KIFC1 | KIF11 9/4885KIF23 8/4885MAP1LC3B 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.